Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ABLi Therapeutics is pioneering innovative treatments for neurodegenerative diseases by targeting dysfunctional Abelson Tyrosine Kinases (Abl/c-Abl) with small-molecule inhibitors. Using our proprietary RAMP™ (Re-engineering Approach with Metabolism Preserved) platform, we optimize clinically validated kinase inhibitors to enhance brain penetration, potency, and safety. Our approach aims to intervene at the root of disease p...
ABLi Therapeutics is pioneering innovative treatments for neurodegenerative diseases by targeting dysfunctional Abelson Tyrosine Kinases (Abl/c-Abl) with small-molecule inhibitors. Using our proprietary RAMP™ (Re-engineering Approach with Metabolism Preserved) platform, we optimize clinically validated kinase inhibitors to enhance brain penetration, potency, and safety. Our approach aims to intervene at the root of disease progression, offering promising therapies for conditions driven by kinase dysregulation.

List your booth number for exhibitions, ask us